 Email this article to a friend  Printable Version FREE Email Newsletter
(NaturalNews) A consortium of researchers, supported by the National Institutes of Health's National Institutes on Aging and coordinated by the University of California-San Diego, will be conducting a nationwide clinical trial to study the effects of an omega-3 fatty acid on the progression of Alzheimer's disease.
Researchers will study 400 patients with mild to moderate Alzheimer's disease at 51 sites across the United States. All participants will be above the age of 49.
Approximately 60 percent of the participants will receive a daily supplement of 2 grams of docosahexaenoic acid (DHA), a type of omega-3; the other 40 percent will receive a placebo instead. The study will be conducted with a double-blind procedure, meaning that neither patients nor researchers will know which patients are receiving the placebo until after the study is completed.
The DHA will be donated by Martek Biosciences Company, a major manufacturer of DHA and a promoter of the fatty acid as a food additive.
The researchers will monitor the participants for 18 months, measuring the progress of Alzheimer's with a variety of cognitive tests. In addition, researchers will monitor the physical and biological markers of the disease, including brain atrophy and protein concentration in blood and spinal fluid.
Studies on mice have suggested that DHA may be effective in slowing the progression of Alzheimer's, but the upcoming study will be the first human trial.
DHA occurs naturally in microalgae and accumulates in aquatic animals higher up the food chain. For this reason, the most common, non-synthesized dietary source of DHA is fish oil. The body can synthesize small quantities of DHA upon the consumption of another omega-3 called a-linolenic acid, which is found in a variety of seeds and nuts.
There are an estimated 5 million Alzheimer's patients in the United States, It was the country's seventh leading cause of death in 2004.
Get articles like this delivered to you FREE in our popular email newsletter
|
(FREE) Thursday evening, Nov. 12 at 6pm Pacific (9pm Eastern), call in to hear the NaturalNews Talk Hour with special guest Dr. Caldwell Esselstyn - "Making Yourself Heart Attack Proof" Register via email to receive call-in number:
|
|
Explore NaturalPedia.com, the internet's largest natural health encyclopedia of knowledge, covering over 50,000 topics. It's free!
Visit NaturalPedia.com.
|
 FREE Report: The Five Best Anti-Viral Products to Beat Influenza, Swine Flu, Bird Flu and SARS
• Top anti-viral remedies
• Where to get them now
• Four things to avoid
• Become self-reliant
• Boost your family safety
Click here to read the FREE report now.
|
W.H.O. Declares Global Pandemic
Turn FEAR into Confidence!
Listen to the complete 3.5 hour recording on 4 audio CDs of the Health Ranger's Swine Flu Advanced Preparedness Course, covering natural anti-virals, family safety, infrastructure disruptions, quarantine, preparedness gear and much more.
Testimonials:
"Mike Adams' preparedness course turned our fears into confidence. This is POWERFUL information, coming from a trusted source. If you want to save yourself countless hours researching and getting prepared and if you want to do everything in your power to protect your family, I highly recommend the Health Ranger’s Advanced Preparedness Course."
- N. Nelson (Arizona)
"This is packed information no one should miss."
- T. Valenzuela
"Thanks Mike... during this class you covered prevention and preparedness from A to Z with integrity, brave honesty and outstanding knowledge! Thank you for your steadfast, thorough and cool-headed approach to well being. With deep gratitude for your service." - Bev
Available NOW for immediate shipping.
100% satisfaction guarantee
 NEW Product: Valley of Longevity Shampoo from the Health Ranger
• 98% Organic
• 100% Natural
• 100% Fragrance Free!
• No SLS
• No Parabens
• No synthetic chemicals
• FREE shipping in U.S. on orders over $75
Click here to read more...
|
|
|
Email this article to a friend
Share this article on: 
